Skip to main content

Table 1 Baseline clinical characteristics

From: Dose and time responses of vitamin D biomarkers to monthly vitamin D3 supplementation in overweight/obese African Americans with suboptimal vitamin d status: a placebo controlled randomized clinical trial

Variable Study groups P-value
  Placebo (n = 17) 600 IU/day (n = 17) 2000 IU/day (n = 18) 4000 IU/day (n = 18)  
Age (years) 27.78 ± 2.6 26.19 ± 2.5 24.38 ± 2.0 25.51 ± 2.2 0.77
Male/Femalea 4/12 2/13 3/14 2/15 0.76
Height (cm) 164.28 ± 2.1 164.60 ± 2.0 163.84 ± 2.4 164.20 ± 1.7 0.99
Weight (kg) 98.42 ± 6.7 93.39 ± 3.7 99.16 ± 5.0 92.77 ± 4.8 0.74
BMI (kg/m2) 36.19 ± 2.0 34.56 ± 1.4 37.08 ± 1.9 34.42 ± 1.7 0.66
Serum 25(OH)D (ng/mL) 15.88 ± 1.4 14.00 ± 0.8 15.93 ± 1.0 13.25 ± 1.0 0.21
Plasma iPTH (pg/mL)# 47.32 ± 3.6 59.60 ± 7.8 50.60 ± 4.2 62.00 ± 8.8 0.32
Plasma 1,25(OH)2D (pg/mL) 34.04 ± 1.9 37.40 ± 1.8 35.18 ± 2.3 32.70 ± 1.1 0.46
Plasma FGF-23 (pg/mL)# 6.53 ± 0.9 6.92 ± 0.8 8.57 ± 1.6 6.57 ± 0.9 0.81
Plasma Phosphorus (mg/dL)# 3.74 ± 0.2 4.01 ± 0.3 3.61 ± 0.1 3.80 ± 0.1 0.71
Urine Ca/Cr ratio 0.08 ± 0.05 0.05 ± 0.03 0.10 ± 0.05 0.08 ± 0.05 0.09
  1. Values are presented as mean ± s.e.m
  2. BMI Body mass index, 25(OH)D Serum 25-hydroxyvitamin D, Plasma 1,25(OH) 2 D 1,25-dihydroxyvitamin D, iPTH Intact parathyroid hormone, FGF-23 Fibroblast Growth Factor-23, Ca/Cr Calcium/creatinine ratio
  3. aGroup differences analyzed using chi-square test
  4. #Group differences analyzed using Kruskal-Wallis test